Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study - PubMed (original) (raw)
Clinical Trial
. 2000 Dec 15;96(13):4075-83.
K J Kopecky, P A Cassileth, D H Harrington, K S Theil, A Mohamed, E Paietta, C L Willman, D R Head, J M Rowe, S J Forman, F R Appelbaum
Affiliations
- PMID: 11110676
Free article
Clinical Trial
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
M L Slovak et al. Blood. 2000.
Free article
Abstract
The associations of cytogenetics with complete remission (CR) rates, overall survival (OS), and outcomes after CR were studied in 609 previously untreated AML patients younger than 56 years old in a clinical trial comparing 3 intensive postremission therapies: intensive chemotherapy, autologous transplantation (ABMT), or allogeneic bone marrow transplantation (alloBMT) from matched related donors. Patients were categorized into favorable, intermediate, unfavorable, and unknown cytogenetic risk groups based on pretreatment karyotypes. CR rates varied significantly (P <.0001) among the 4 groups: favorable, 84% (95% confidence interval [CI], 77%-90%); intermediate, 76% (CI, 71%-81%); unfavorable, 55% (CI, 48%-63%); and unknown, 54% (CI, 33%-74%). There was similar significant heterogeneity of OS (P <.0001), with the estimated relative risk of death from any cause being 1.50 (CI, 1.10-2.05), 3. 33 (CI, 2.43-4.55), and 2.66 (CI, 1.59-4.45) for the intermediate, unfavorable, and unknown risk groups, respectively, compared with the favorable group. In multivariate analyses, the effects of cytogenetic risk status on CR rate and OS could not be explained by other patient or disease characteristics. Among postremission patients, survival from CR varied significantly among favorable, intermediate, and unfavorable groups (P =.0003), with significant evidence of interaction (P =.017) between the effects of treatment and cytogenetic risk status on survival. Patients with favorable cytogenetics did significantly better following ABMT and alloBMT than with chemotherapy alone, whereas patients with unfavorable cytogenetics did better with alloBMT. Cytogenetic risk status is a significant factor in predicting response of AML patients to therapy; however, to tighten treatment correlates within genetically defined AML subsets, a significantly larger leukemia cytogenetic database is warranted.
Similar articles
- The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. Visani G, et al. Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review. - Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Byrd JC, et al. Blood. 2002 Dec 15;100(13):4325-36. doi: 10.1182/blood-2002-03-0772. Epub 2002 Aug 1. Blood. 2002. PMID: 12393746 Clinical Trial. - Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Bloomfield CD, et al. Cancer Res. 1998 Sep 15;58(18):4173-9. Cancer Res. 1998. PMID: 9751631 Clinical Trial. - The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. Grimwade D, et al. Blood. 1998 Oct 1;92(7):2322-33. Blood. 1998. PMID: 9746770 Clinical Trial. - Adult acute leukemia.
Cripe LD. Cripe LD. Curr Probl Cancer. 1997 Jan-Feb;21(1):1-64. doi: 10.1016/s0147-0272(97)80006-2. Curr Probl Cancer. 1997. PMID: 9058027 Review.
Cited by
- Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.
Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Goyal SD, et al. Bone Marrow Transplant. 2015 Aug;50(8):1057-62. doi: 10.1038/bmt.2015.82. Epub 2015 Apr 27. Bone Marrow Transplant. 2015. PMID: 25915806 Free PMC article. - The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.
Holter-Chakrabarty JL, Pierson N, Zhang MJ, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, Epstein RB, Lazarus HM, Olsson RF, Selby GB, Williams KM, Cooke KR, Pasquini MC, McCarthy PL. Holter-Chakrabarty JL, et al. Biol Blood Marrow Transplant. 2015 Jul;21(7):1251-7. doi: 10.1016/j.bbmt.2015.03.017. Epub 2015 Mar 31. Biol Blood Marrow Transplant. 2015. PMID: 25840335 Free PMC article. - Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R, Duggal S, Lin Y, Smith C, Boyiadzis M. McLaughlin B, et al. Int J Hematol. 2012 Dec;96(6):743-7. doi: 10.1007/s12185-012-1192-9. Epub 2012 Nov 7. Int J Hematol. 2012. PMID: 23132594 Clinical Trial. - High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.
Yin JY, Tang Q, Zhai LL, Zhou LY, Qian J, Lin J, Wen XM, Zhou JD, Zhang YY, Zhu XW, Deng ZQ. Yin JY, et al. Tumour Biol. 2015 Dec;36(12):9711-6. doi: 10.1007/s13277-015-3731-5. Epub 2015 Jul 9. Tumour Biol. 2015. PMID: 26152287 - Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.
Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakamae H, Taguchi J, Sakura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, Fukuda T. Yanada M, et al. Haematologica. 2012 Jun;97(6):915-8. doi: 10.3324/haematol.2011.058289. Epub 2011 Dec 16. Haematologica. 2012. PMID: 22180431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources